Fate Therapeutics (FATE) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Fate Therapeutics (FATE) over the past year, gaining 129.0% versus a gain of 54.7%. Over five years, IPSC leads with a -93.4% price change compared with -96.5% for FATE. Fate Therapeutics is the larger company by market cap ($245.6 million vs $224.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | IPSC |
|---|---|---|
| Share price | $2.05 | $1.24 |
| Market cap | $245.63M | $224.53M |
| 1-day change | -4.65% | -3.12% |
| YTD return | +119.39% | +28.64% |
| 1-year return | +54.68% | +128.98% |
| 5-year return | -96.49% | -93.37% |
| EPS (TTM) | $-1.05 | $-0.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $3.04 |
| 52-week low | $0.95 | $0.435 |
| Distance from 52-week high | -36.53% | -59.21% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +180.00% | +283.06% |
| Average volume | 1.89M | 649.61K |
| Shares outstanding | 119.82M | 181.08M |
| Employees | 161 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed FATE by 74.3 percentage points over the past year.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
FATE vs IPSC FAQ
Which is bigger, Fate Therapeutics or Century Therapeutics?
Fate Therapeutics (FATE) is larger, with a market capitalization of $245.63M compared with $224.53M for Century Therapeutics (IPSC).
Which stock has performed better over the past year, FATE or IPSC?
IPSC returned +128.98% over the past 12 months, compared with +54.68% for FATE (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.